177 related articles for article (PubMed ID: 36935014)
21. Novel heterozygous
Rossano M; Conti EA; Bocca P; Volpi S; Mastrangelo A; Cavalli R; Gattorno M; Minoia F; Filocamo G
Front Immunol; 2023; 14():1288675. PubMed ID: 38124732
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
23. Oral manifestations of patients with lupus erythematosus.
Brennan MT; Valerin MA; Napeñas JJ; Lockhart PB
Dent Clin North Am; 2005 Jan; 49(1):127-41, ix. PubMed ID: 15567365
[TBL] [Abstract][Full Text] [Related]
24. [Systemic therapy of cutaneous lupus erythematosus].
Ochsendorf F
J Dtsch Dermatol Ges; 2004 Mar; 2(3):229-30; author reply 230. PubMed ID: 16281642
[No Abstract] [Full Text] [Related]
25. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
26. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
27. [Systemic lupus erythematosus: cutaneous/articular injuries].
Sociedade Brasileira de Reumatologia
Rev Assoc Med Bras (1992); 2006; 52(6):384-6. PubMed ID: 17242769
[No Abstract] [Full Text] [Related]
28. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
29. Emerging therapies for cutaneous lupus erythematosus.
Borucki R; Werth VP
Cutis; 2020 Jun; 105(6):276-277. PubMed ID: 32716989
[No Abstract] [Full Text] [Related]
30. Innovative management of lupus erythematosus.
Knott HM; Martínez JD
Dermatol Clin; 2010 Jul; 28(3):489-99. PubMed ID: 20510759
[TBL] [Abstract][Full Text] [Related]
31. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
32. Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?
Nakayamada S; Tanaka Y
Expert Opin Investig Drugs; 2023; 32(10):901-908. PubMed ID: 37753834
[TBL] [Abstract][Full Text] [Related]
33. Beneficial effect of hydroxychloroquine on cutaneous vasculitis in a Japanese patient with systemic lupus erythematosus.
Kibune N; Shimomura Y; Hasegawa A; Saeki T; Umemori Y; Abe R
J Dermatol; 2017 Apr; 44(4):e52-e53. PubMed ID: 27569899
[No Abstract] [Full Text] [Related]
34. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase inhibition in complement component 1 deficiency.
Wolf C; Brück N; Koss S; Griep C; Kirschfink M; Palm-Beden K; Fang M; Röber N; Winkler S; Berner R; Latz E; Günther C; Lee-Kirsch MA
J Allergy Clin Immunol; 2020 Dec; 146(6):1439-1442.e5. PubMed ID: 32325142
[No Abstract] [Full Text] [Related]
36. The immunopathology of cutaneous lupus erythematosus.
Kirchhof MG; Dutz JP
Rheum Dis Clin North Am; 2014 Aug; 40(3):455-74, viii. PubMed ID: 25034156
[TBL] [Abstract][Full Text] [Related]
37. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
38. Pimecrolimus 1% cream for cutaneous lupus erythematosus.
Kreuter A; Gambichler T; Breuckmann F; Pawlak FM; Stücker M; Bader A; Altmeyer P; Freitag M
J Am Acad Dermatol; 2004 Sep; 51(3):407-10. PubMed ID: 15337984
[TBL] [Abstract][Full Text] [Related]
39. Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations.
Ting WW; Sontheimer RD
Lupus; 2001; 10(3):171-84. PubMed ID: 11315348
[TBL] [Abstract][Full Text] [Related]
40. Hydroxychloroquine dose tapering or discontinuation in cutaneous lupus erythematosus after remission: A retrospective multicenter cohort study of 56 patients.
Sonigo G; Jachiet M; Bessis D; Cordel N; Faucon C; Petit A; Cordoliani F; Bagot M; Senet P; Barbaud A; Bouaziz JD; Francès C; Chasset F;
J Am Acad Dermatol; 2022 Jul; 87(1):203-206. PubMed ID: 34333080
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
